Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.